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Release of microparticles (MPs) from blood cells may occur
upon various activation signals. MPs from neutrophil and
platelet have been studied in systemic infectious diseases
and cardiovascular diseases, respectively. They are here
investigated in common nephropathies including vasculitis
and dialysis, two conditions characterized by neutrophil
activation. Flow cytometry analysis of neutrophil-derived
(CD66b-positive) and platelet-derived (CD41a-positive) MPs
was performed on 213 plasma samples from patients with
various nephropathies, including 46 patients with vasculitis
and 40 hemodialysis patients. MPs released ex vivo, during
neutrophil activation in whole blood, were also measured in
these patients. Correlations with clinical parameters and
creatinine clearance were evaluated. The results show that
MPs present in plasma from patients or healthy controls
are from various origins: platelet-derived (38722%),
neutrophil-derived (2.873.8%) MPs, mixed aggregates of
neutrophil/platelet MPs (28715%) or neither from
neutrophil or platelet (null) 31720%. Acute vasculitis
showed the highest level of all types of MPs, while other
nephropathies did not result in significant changes of MP
levels. A significant increase was observed during
hemodialysis sessions. In patients with renal failure, no
correlation was seen between MP levels and creatinine
clearance. In conclusion, neutrophil and platelet MP levels are
non-specific markers of neutrophil activation during
vasculitis acute phase and dialysis-induced inflammation.
Circulating aggregates of neutrophil/platelet MPs co-express
adhesion molecules of both cell types and may be thus
endowed with inflammation and coagulation- thus
modulating properties.
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Polymorphonuclear neutrophils play a central role in
inflammation acute phase, via their degranulation response
and respiratory burst.1 During early activation, neutrophils
are capable, as platelets, to release microparticles (MPs).2
MPs, or ectosomes, are plasma membrane vesicles which
express markers of the parent cells outer membrane and are
released by many cell types upon activation or during
apoptosis.3 They are distinct from exosomes, smaller
membrane vesicles which result from the exocytosis of
endocytic multivesicular bodies.4
Neutrophil MPs carry a large set of cell adhesion molecules
and proteases such as proteinase 3 or elastase.5 The pro-infla-
mmatory or anti-inflammatory functions of these neutrophil
MPs are still under discussion.6,7 The release of neutrophil
MPs is well described during systemic infectious diseases
or in severely injured patients.8,9 On the other hand, platelet
MPs are involved in cardiovascular diseases with coagulation
abnormalities as acute coronary syndromes10,11 or diabetes.12
Similarly, endothelial MPs are relevant markers of endothelium
dysfunction.13 During chronic renal failure (CRF) progression,
pro-inflammatory cytokines are increased and inflammation
could explain in part the decline of renal function because of
accelerated atherosclerosis. Platelet MPs have been reported to
be increased during CRF14 and could participate in producing
hypercoagulation. So far, neutrophil MPs have not been studied
in patients with nephropathies or CRF. The aim of the present
study was to evaluate neutrophil and platelet MPs in
nephropathies, including vasculitis and end-stage renal failure,
since neutrophils are particularly involved in both the
development of active vasculitis and the effect of the dialysis
membranes on inflammation. We show that platelet and
neutrophil MPs are significantly increased in patients with
active vasculitis and during hemodialysis.
RESULTS
Neutrophil-derived, platelet-derived, and mixed MPs in
plasma and after ex vivo neutrophil activation in healthy
donors
Figure 1 shows flow cytometry dot blots analysis of plasma
MPs recovered from whole blood of a healthy donor, before
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and after in vitro incubation with tumor necrosis factor alpha
(TNFa) and the formyl-peptide fMLP (N-formyl-L-methionyl-
L-leucyl-L-phenylalanine). Figure 1a shows the size (forward
scatter channel, FSC) and densitometry (side scatter channel,
SSC) of MPs (R2), as compared to the 3 mm calibrated latex
beads (R1). Events present in R2, which included most spun-
down MPs except for rare high size events that could be
contaminating blood cells, were gated to count immunola-
beled MPs (Figure 1b). CD66b-labeled MPs represent
neutrophil-derived MPs (Neutro-MPs) and CD41a-labeled
MPs are platelet-derived MPs (Pl-MPs). Double-labeled
CD66b- and CD41a-positive MPs reveal the presence of
neutrophil/platelet MP aggregates (Mixed MPs). One should
point out that in vitro formation of MP aggregates had been
prevented by adding ethylene diamine tetra-acetic acid to the
collected plasma, to block novel Ca2þ -dependent adhesion
via P-selectin. CD66b- and CD41a-negative events, included
in the lower left quadrant, are called null MPs. FSC/SSC dot
blots of each MP population (Pl, Mixed, Neutro, and Null),
in Figure 1c, show that they are all similar in size, but MPs
with 100–1000 FSC, presumably representing MP aggregates,
were mostly observed in mixed MPs and absent in the platelet
MPs gate. Quantification of each MP type was performed by
using the latex beads (R1) as an internal standard, as
described in Materials and Methods.
Figure 2 analyses the release of MPs resulting from ex vivo
neutrophil activation in whole blood from healthy donors.
Figure 2a shows that a 20-min incubation of whole blood at
371C with 1 mM fMLP induces a significant release of Neutro-
and Mixed MPs, as defined above, while the number of
platelet MPs does not change. Figure 2b shows the effect of
whole blood activation by TNF-a and fMLP on total CD66b-
positive MPs, that is, Neutro- and Mixed MPs. The addition
of 1 ng/ml TNF-a or 1 mM fMLP was sufficient to induce a
significant increase of these MPs (91744 and 118749
103 MPs/ml respectively, as compared to 52719 103 MPs/ml
in control unactivated blood, Pp0.01). The highest level
(2767198 103 MPs/ml) was observed when fMLP 1 mM was
associated with 10 ng/ml TNF-a, revealing the priming effect
of TNF-a on neutrophil responses.15,16 The number of
released MPs in this condition was greatly variable among
donors but significantly higher than with fMLP alone.
As reported by Gasser et al.,5 we confirmed by flow
cytometry that neutrophil MPs express membrane PR3 on
their membrane (data not shown).
The number of null MPs also increased after neutrophil
activation by fMLP in whole blood (1517132 103 up to
4747248 103, n¼ 17, Po0.0001, data not shown). The
phenotype of these null MPs was investigated using
antibodies to non-platelet and non-neutrophil markers (data
not shown): more than 80% of null MPs expressed
phosphatidylserine on their surface, as shown by the binding
of annexin V and confirming previous reports.17 They are
thus membrane particles rather than protein aggregates such
as fibrin or von Willebrand factor polymers. They were
negative in lymphocyte marker CD3, monocyte marker
CD14, endothelial marker CD146, and negative in CD63,
a marker of exosomes recently described in plasma.18 In
all, 40–80% of null MPs expressed an erythrocyte
marker, glycophorin C. The reddish color of the plasma,
after ex vivo neutrophil activation in whole blood, indeed
shows that neutrophil activation induces hemolysis,
presumably via the release of reactive oxygen species. Null
MPs could thus include erythrocyte ghosts or erythrocyte-
derived ectosomes, similar to those released following
complement attack.19
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Figure 1 | Flow cytometry analysis of MPs. (a) MPs were first
identified by size on an FSC–SSC analysis. Note the 3 mm latex beads
(arrow), used as an internal control and counted in gate R1 to
quantify MPs, as described in Materials and Methods. (b) MPs isolated
from a healthy donor blood, before and after ex vivo activation with
10 ng/ml TNF-a and 1 mM fMLP, were labeled with a platelet-specific
antibody (anti-CD41a) and neutrophil-specific antibody (anti-CD66b).
Fluorescence analysis of MPs (gated in R2 of FSC–SSC dot blot)
allowed to distinguish isolated platelet-derived MPs (pl-MPs),
neutrophil-derived MPs (neutro-MPs), and aggregates of both types
of MPs (mixed-MPs). MPs present in the lower left quadrant are null
MPs. (c): FSC–SSC analysis of each MP subtype, as defined in (b) by
fluorescence analysis.
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MP levels in patients with nephropathies
MP levels according to the pathological classification are
given in Table 1 and schematized in Figure 3. The
distribution of circulating MPs was similar in all pathologies
as in healthy controls, that is, 2.873.8% Neutro- (1.1–4.5%),
28715% mixed Pl/neutro-MPs (22–38%), 38722% platelet
MPs (27–43%), 31720% null MPs (18–39%). The most
striking result was obtained in acute vasculitis, where the
levels of all MP types were increased six times as compared to
normal controls. An important point was a large individual
variation within subgroups (Table 1). When using a multiple
comparison test, highly significant differences were observed
between acute vasculitis and healthy controls, for all types of
MPs. A modest but significant increase of mixed MPs was
also observed in chronic vasculitis and in tubulo-interstitial
nephritis. Neutro-MPs were found to be significantly in-
creased in both acute and chronic vasculitis, in tubulo-
interstitial nephritis, and in glomerular nephropathies
with immune deposits (IgA nephropathy/membranous
nephropathy). The low and highly variable level of neutro-
MPs probably explains this lack of specificity. When total
CD66b-positive Neutro-MPs (neutro-MPsþmixed MPs)
were considered, the difference with healthy controls was
again highly significant in acute vasculitis (Po0.001), but less
significant in chronic vasculitis and tubulo-interstitial
nephritis (P¼ 0.02 and 0.04, respectively; data not shown).
When total CD41a-positive Pl-MPs (pl-MPsþmixed MPs)
were considered, a significant difference was only observed in
acute vasculitis (Po0.001; data not shown). An increase of
Null MPs number was also observed in acute vasculitis
(6457819 103) and, to a lesser extent, in tubulo-interstitial
nephritis (2897481 103) and IgA/MN (3307666 103),
when compared to controls (1797152 103) (data not
shown).
Concerning clinico-biological parameters, no correlation
was observed of MP levels with age (r¼ 0.06; P¼ 0.4, for
neutrophil-derived, CD66b-positive MPs; r¼ 0.05; P¼ 0.45
for platelet-derived, CD41a-positive MPs) or with serum C
reactive protein (r¼ 0.15; P¼ 0.06 for neutrophils; r¼ 0.07;
P¼ 0.4 for platelets). A slight positive correlation was
observed, however, between Neutro-MPs and circulating
neutrophil counts (r¼ 0.2, P¼ 0.02) or between Pl-MPs and
circulating platelet counts (r¼ 0.3; Po104).
Decreased creatinine clearance was not correlated with an
increase of neutrophil-derived (r¼ 0.1; P¼ 0.2) or platelet-
derived (r¼ 0.06; P¼ 0.5) MPs level. We even observed an
opposite trend when four patients subgroups were defined
according to the creatinine clearance (Figure 4)
Mp levels in patients with vasculitis
When chronic and acute vasculitis were compared separately
with healthy controls, a significant increase of Neutro- and
Mixed MPs was observed in acute and, to a lesser extent, in
chronic vasculitis, while platelet MPs were only increased in
acute vasculitis (Figure 5a). MP levels were further increased
during acute phases of the disease. This appears clearly in
Figure 5b, where the level of CD66-positive MPs (neutro-
MPs and mixed MPs) was strikingly higher in the plasma of
patients with acute vasculitis, when compared to chronic
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Figure 2 | Analysis of MPs released during ex vivo neutrophil
activation in whole blood from healthy donors. (a) Blood samples
were incubated for 20 min at 371C with or without 1 mM fMLP. MPs
were isolated and labeled to be analyzed by flow cytometry, as
described in Figure 1. Results are given as the mean7s.d. (n¼ 20
experiments) of the number of each MPs type, recovered from 1 ml of
plasma. MP levels obtained without or with fMLP are compared
(*Po0.05; **Po0.01; ***Po0.001). (b) Mean levels of CD66b-positive
MPs (Neutro-MPsþMixed MPs) obtained after ex vivo neutrophil
activation with TNF-a and/or fMLP.
Table 1 | MP levels in nephropathies
n
Age
(years)
Creatinine
clearance
Neutro-MPs
( 103/ml)
Mixed-MPs
( 103/ml)
Pl-MPs
( 103/ml)
Controls 20 NR NR 271.5 49718 1477238
Nephrosclerosis 20 60716 41728 675.7 89762 2697514
Diabetic nephropathy 10 57715 34724 677.3 76751 1157175
Tubulo-interstitial nephritis 19 45721 40729 18722 (Po0.001) 99778 (P=0.001) 2087250
MCN/FSG 7 36714 88746 473.7 92758 1907226
IgAN/MN 18 51714 52725 14715 (P=0.001) 88743 1567176
Lupus nephropathy 16 39721 65735 8713 72741 2107144
Chronic vasculitis 29 51715 61724 774.7 (P=0.01) 96760 (P=0.001) 4457581
Acute Vasculitis 17 54714 59721 23719 (Po0.001) 238783 (Po0.001) 102571982 (P=0.005)
Urological diseases 17 49720 42723 7711 76747 2267343
Others 21 62715 36716 11727 101780 2917415
FSG, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; MCN, minimal changes nephropathy; MN, membranous nephropathy; Pl-MPs, platelet-derived MPs.
Clearance was reported in ml/min. NR, not recorded; MP, microparticles. Bold characters underline numbers significantly different from normal controls (Po0.05).
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vasculitis. The large standard deviation among patients is a
characteristic of MPs detection, even in healthy patients.20
Nevertheless, we observed no overlap between patients with
acute vasculitis and healthy controls (Figure 5b).
Two patients with Wegener granulomatosis were analyzed
before and after treatment: In the first patient, an 80%
decrease of CD66b-positive MPs and a 6% decrease of
CD41a-positive MPs were observed 3 days after steroid
pulses. In the second patient, a 48% decrease of CD66b-
positive MPs and a 27% decrease of CD41a-positive MPs
were observed 1 month later (data not shown).
MP levels in hemodialysis patients
MP levels before and after the hemodialysis session are given
in Table 2 and Figure 6a. Neutro-PMs, but not Pl-MPs were
significantly enhanced in patients before hemodialysis, when
compared to healthy controls (Figure 6b). A further
significant increase of both neutrophil MPs and platelet
MPs was observed after hemodialysis. The number of null
MPs did not change (1647199 before and 1237139 after
dialysis, n¼ 33, P¼ 0.28) (data not shown).
Concerning subgroups of hemodialysis patients, no
significant difference in MP levels was observed between
patients with less or more than 6 months of hemodialysis,
patients without or with established vasculopathies, or
patients hemodialysis with synthetic or celluloid membranes.
Ex vivo MPs release
Ex vivo neutrophil activation in whole blood from patients
with acute vasculitis (Figure 7a) or blood recovered after
hemodialysis (Figure 7b) did not result in a significant
increase of neutrophil MPs, as compared to the initial
number of circulating MPs. This contrasted with what was
observed with normal controls, with patients with chronic
vasculitis, or with patients before hemodialysis.
This suggested that the ability of neutrophils to further
release MPs upon activation ex vivo was exhausted in patients
with acute vasculitis or after the contact between circulating
cells and dialysis membranes.
DISCUSSION
This study shows that neutrophil and platelet MPs are
important in vivo markers of neutrophil activation, in
patients with vasculitis and during hemodialysis-induced
inflammation.
An increase of circulating endothelial cells and endothelial
MPs has been previously reported in patients with vascu-
litis.21,22 Surprisingly, neutrophil MPs were not investigated,
in spite of the central role of neutrophils in anti-neutrophil cyto-
plasmic antibody-associated vasculitis. In our study, patients
with acute vasculitis clearly had the highest levels of circulat-
ing neutrophil MPs. These levels were significantly lower in
chronic vasculitis and may thus be considered as markers
of disease activity. With regard to treatment response, we
tested two patients with Wegener granulomatosis before and
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Figure 5 | Circulating MPs in vasculitis. (a) MPs were isolated from
whole blood, labeled, and characterized as in Figure 1. Neutro-,
mixed, and pl-MPs levels from 29 patients with chronic vasculitis and
17 patients with acute vasculitis were compared to 21 healthy
controls (mean7s.d.; NS, non-significant, *Po0.05; **Po0.01;
***Po0.001). (b) Total neutrophil-derived CD66b-positive MP
(neutro- and mixed-) levels of plasma analyzed in (a). Note the
absence of overlap between controls and acute vasculitis. The
significantly higher levels observed in chronic vasculitis are further
increased in acute episodes.
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after steroid treatment and observed a striking decrease of
Neutro-MPs and, to a lesser extent, of Pl-MPs. A larger
prospective study would be of interest to analyze MP levels in
relation to disease activity and treatment. One should keep in
mind, however, that neutrophil MPs strongly increase during
severe infectious diseases8 and should be cautiously used as a
marker of acute vasculitis relapses in patients with immuno-
suppressive treatment.
Patients with tubulo-interstitial nephritis, in our study,
also had high levels of circulating MPs. Both renal and extra-
renal inflammation may be involved in these patients, since
acute tubulo-interstitial inflammation was present and
primary immune disorders with systemic manifestations
were identified in 9/19.
Neutrophil MP levels had not been previously studied
during CRF progression. Platelet MP increases have been
reported, but with a range overlap with the healthy control
group and without precise absolute number of MPs.14 In our
study, we found no significant increase of neutrophil MP
levels during progression of renal failure. By contrast, we
observed increased levels of Neutro-MPs in hemodialysis
patients. This discordance is important to consider in the
light of the inhibitory effects of uremic toxins, such as
p-cresol, on neutrophil activation.23 Moreover, in CRF,
neutrophil activation does not result in increased cytosolic
Ca2þ , a mechanism involved in MPs release.24 Thus, it is
possible that uremic toxins inhibit MPs release by preventing
neutrophil activation.
During the hemodialysis session, the levels of all three
types of MPs (Pl-MPs, neutro-MPs, and mixed MPs) were
significantly enhanced. Detrimental effects of hemodialysis
membranes (and/or dialysate itself) on inflammation status
are well documented.25,26 These effects involve direct
interaction between membranes and/or endotoxin and the
complement system and circulating cells. Pro-inflammatory
effects of celluloid membranes are higher than synthetic
Table 2 | MP levels in hemodialysis patients
CD66ba ( 103) CD41ab ( 103) Neutro-MPs ( 103) Mixed ( 103) Pl-MPs ( 103)
All patients (BD) 1157114 2647444 13714 987104 1567345
P (compared to controls) 0.003 0.58 o0.001 0.02 0.36
All patients (AD) 1977255 68771247 417170 1567188 53271139
P (compared to BD) 0.001 0.008 0.88 0.006 0.018
Before dialysis After dialysis
CD66ba ( 103) CD41ab ( 103) CD66ba ( 103) CD41ab ( 103)
Dialysis 46 months 102774 2257187 2167261 82571292
Dialysiso6 months 1217141 2827593 1787255 55071220
With vasculopathies 104758 1617142 2557302 83471368
Without vasculopathies 1157135 3097536 1677228 61171202
Synthetic membranes 1087147 2607593 1717254 66571228
Celluloid membranes 114764 2477194 2237261 71071300
AD, after dialysis; BD, before dialysis; MP, microparticles; Pl-MPs, platelet-derived MPs.
aNeutro-MPs+Mixed MPs.
bPl-MPs+Mixed MPs.
Bold characters underline numbers significantly different from normal controls (Po0.05).
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Figure 6 | Circulating MPs in hemodialysis. (a) pattern of pl-MPs,
neutro-MPs, and mixed-MPs recovered from the blood of 40 patients
with renal failure, before and after hemodialysis. (b) Total neutrophil-
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Figure 7 | Effect of ex vivo neutrophil activation in whole blood
from (a) patients with vasculitis and (b) patients undergoing
hemodialysis. Mean7s.d. of CD66b-positive (Neutro- and Mixed-)
MP levels were measured in the blood (circulating) and after
incubation of whole blood with 1 mM fMLP at 371C (ex vivo activated).
NS, non-significant, *Po0.05; **Po0.01; ***Po0.001.
1420 Kidney International (2006) 69, 1416–1423
o r i g i n a l a r t i c l e L Daniel et al.: Neutrophil and platelet microparticles in nephropathies
ones.27 We found a 30% increase of neutrophil MP levels
with celluloid membranes, when compared to synthetic
membranes, but without reaching statistical significance.
In vitro MPs release was also investigated, during
neutrophil activation in whole blood. We observed a priming
effect of TNF-a, leading to an enhanced release of neutrophil
MPs in response to fMLP. This priming effect has also been
described for the oxidative burst.15,16 We thus anticipated
that circulating TNF-a, present in patients with vasculitis,28,29
would result in a high ex vivo MP release, following fMLP
stimulation. In fact, we obtained the opposite results, since
neutrophils from vasculitis patients poorly respond to ex vivo
activation by fMLP, when compared to healthy controls. This
could be because of in vivo activation of patients’ neutrophils,
resulting in exhaustion of their MPs release potential.
Similarly, neutrophils from post-dialysis blood samples did
not show a significant increase of CD66b-positive MPs
during further ex vivo activation by fMLP. This suggests that
inflammation stimuli such as C5a, during the hemodialysis
session, had de-sensitized neutrophil fMLP receptors.30
In our study, we found that the increase of neutrophil MPs
was constantly accompanied by an increase of platelet MPs.
Although platelets do not express receptors for inflammatory
stimuli, such as of TNF receptors or the fMLP-receptor,31,32
they can be activated indirectly by neutrophil-derived
proteases33,34 and neutrophil/platelet aggregates have been
described following neutrophil-specific stimulation.35,36
Moreover, neutrophil MPs, by themselves, contain platelet-
activating-factor), thus leading to a secondary release of
platelet MPs after neutrophil activation.37
Interestingly, we here observe, for the first time, that 90%
of circulating Neutro-MPs are in fact mixed aggregates of
platelet-derived and neutrophil-derived MPs, since they bear
both neutrophil-specific (CD66b) and platelet-specific
(CD41a) membrane markers. Platelet MPs are known to
adhere to neutrophils via P-selectin, resulting in neutrophil
activation and aggregation.38,39 Similarly, aggregates of
endothelial-derived or monocyte-derived MPs with platelets
have been shown to participate in thrombus formation.40,41
We herein describe the formation of aggregates involving
MPs of different cell types. The occurrence of such aggregates
implies that the MPs number reported in the literature is
generally underscored, since the flow cytometer laser counts
each multi-MPs aggregate as a single event. This fact also
probably explains the large size range of MPs analyzed by
flow cytometry. Further studies should be specifically
performed to evaluate MPs aggregate formation. For
example, we observed that incubation of MPs pellets with a
blocking anti-P-selectin antibody strikingly decreased the
number of mixed-MPs (data not shown).
The potential role of neutrophil MPs in the early
inflammatory response is still under discussion. Neutrophil
MPs are able to increase cytokine and chemokine release by
endothelial cells by an nuclear factor-kB-independent path-
way.6 Moreover, proteinase 3 has been shown to be present
on neutrophil MPs5 and we confirmed this observation (data
not shown). Pro-inflammatory activities of PR3 include its
ability to degrade matrix components, to enhance chemokine
and tissue factor production by endothelial cells,42–44 and/or
provoke endothelial cell apoptosis.45,46 The dissemination of
highly adhesive MPs containing PR3 could thus greatly
enhance inflammatory vascular lesions. On the contrary,
neutrophil MPs could promote the resolution of inflamma-
tion, since they increase the release of transforming growth
factor beta 1 by activated macrophages.7 Platelet MPs could
participate to these modulations by adding new adhesion
molecules to MPs aggregates (GPIIbIIIa, b1 integrins, GPIb,
and P-selectin).47 Platelet MPs also contain bioactive lipids
able to activate cyclooxygenase-2-dependent prostaglandin
production in monocytes and endothelial cells.48 Finally,
upon activation, platelets synthesize IL-1, which is released
and processed on platelet MPs.49,50
In conclusion, the role of MPs, most probably important
in the regulation of inflammation, is only partially delineated.
Further studies to understand and possibly inhibit membrane
remodeling or particle shedding could lead to interesting
therapeutic strategies in inflammatory diseases.
MATERIALS AND METHODS
Patients
Healthy population (n¼ 20) was obtained from the French blood
transfusion center Etablissement Franc¸ais du Sang, with agreement
for studies on healthy volunteers. A total of 213 patients, from
Necker Hospital Nephrology Department and Cochin Hospital
Internal Medicine Department, were studied. Recorded clinical and
biological parameters were diagnosis, sex, age, body weight,
creatininemia, blood cell counts, and serum C reactive protein.
The creatinine clearance, calculated with the Gault and Cockcroft
formula, was considered as a continuous value but four groups were
also defined: X60 ml/min, 30–60 ml/min, 15–30 ml/min, and
o15 ml/min. The study only included patients with no systemic
infectious disease. The 173 patients with nephropathies included 77
women and 96 men (55.5%) with a mean age of 51.6 years (range:
16–93). Renal failure was detected in 135 patients (64%) with a
mean creatinine clearance of 49.7 ml/min (range: 8–80). Diagnosis
subgroups were nephrosclerosis (n¼ 20), diabetic nephropathies
(n¼ 10), tubulo-interstitial nephritis (n¼ 19), minimal changes
nephrophathy/focal segmental glomerulosclerosis (membranous
nephropathy/focal segmental glomerulosclerosis) (n¼ 7), immune
glomerulonephritis (i.e. IgA nephropathies and membranous
nephropathies, n¼ 18), lupus glomerulonephritis (n¼ 16), chronic
vasculitis (n¼ 29), active vasculitis (n¼ 17), urological diseases
(n¼ 17), and other diagnoses (n¼ 21). Tubulo-interstitial nephritis
were secondary to immune interstitial nephritis n¼ 9 (sarcoidosis,
three; isolated renal granulomatas, one; Crohn’s disease one; Sjo¨gren’s
syndrome, one; systemic disease with complex immune disorder, two;
hepatitis C virus-associated hemophagocytic syndrome, one); drug-
induced immunoallergic interstitial nephritis, n¼ 2; multiple myelo-
ma, n¼ 3; lithium toxicity, n¼ 1; unknown origin, n¼ 4.
A total of 46 patients (26.6%) exhibited a vasculitis. The clinical
activity of vasculitis was evaluated according to Birmingham
vasculitis activity score (BVAS in its first version).51 Patients with
active vasculitis (n¼ 17; 37%) were defined as having a score over
7.5 prior to treatment with cytotoxic agents. Vasculitis classification
was done with the Chapel Hill criteria52 and the vasculitis group
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included 29 patients with Wegener’s granulomatosis, seven with
microscopic polyangeitis, seven with Churg and Strauss syndrome,
and three with miscellaneous forms of vasculitis. All patients with
chronic vasculitis had a steroid treatment with or without
immunosuppressive agents.
Patients with end-stage renal failure included 18 men and 22
women with a mean age of 64.9 years (range: 38–93). All patients
were hemodialyzed in the same medical unit (Necker Hospital
Nephrology Department) with standardized proceedings. Only
patients with stable clinical states were selected; hence all patients
had a fistula, none had a catheter. The length of hemodialysis session
was 6 h for all patients. Recorded clinical parameters were the length
of dialysis period (o or X6 months, n¼ 20/40, 50%), the type of
membranes (synthetic or celluloid, n¼ 19/40; 47.5%), and the
presence of vasculopathies based on clinical complications (n¼ 15/
40; 37.5%).
MPs preparation
In total, 10 ml of citrated blood were obtained from each patient and
healthy donor. For ex vivo neutrophil stimulation, blood samples
were incubated 20 min with 1 mM fMLP (Sigma, St Louis, MO, USA)
at 371C with slight shaking. When mentioned, 1 or 10 ng/ml human
recombinant TNFa (PeproTech, Rocky Hill, NJ, USA) was also
added.
After incubation, blood samples were centrifuged for 20 min at
41C at 150 g to remove blood cells. Plasma was further cleared from
cell debris by a 20-min centrifugation at 300 g. Ethylene diamine
(0.2 M) tetra-acetic acid was added to prevent in vitro MPs
aggregation. MPs were recovered, from 1 ml of plasma for each
measurement, by a 30-min centrifugation at 15 000 g. No significant
difference of MPs number was observed between 15 000 g and
100 000 g centrifugations (data not shown). Dry MPs pellets were
stored at 801C until use.
MPs labeling
The following primary antibodies were used: antigen-presenting
cell-labeled anti-CD41a (GPIIb) mAb and mouse IgG1 (Pharmin-
gen, San Diego, CA, USA). Unlabeled anti-CD66b mAb (Beckman/
Coulter, Roissy, France) and mouse IgG1 (Sigma) were biotinylated
with EZ-Link sulfo-NHS-LC-Biotin (Pierce, Rockford, IL, USA),
according to the manufacturer’s instructions.
Frozen MPs pellets were incubated for 20 min at 41C with 1 mg/
ml heat-aggregated (30 min 601C) goat IgG (Sigma), to block Fc-g
receptors, then for 30 min at 41C with primary antibodies or iso-
type controls and washed (30 min at 15 000 g) with cold phos-
phate-buffered saline containing 1% bovine serum albumin and
0.1% sodium azide. To reveal biotinylated primary antibodies,
phycoerythrin-labeled streptavidin (Beckman/Coulter) was then
incubated for 20 min at 41C. MPs were finally resuspended in
phosphate-buffered saline-azide to be analyzed by flow cytometry.
Flow cytometry
After immunolabeling, MPs samples were immediately analyzed on
a Becton Dickinson Facscalibur (Mountain view, CA, USA). MPs
were identified according to FSC and SSC analysis. A logarithmic
gain was selected for FSC and SSC and an acquisition threshold was
set on the FSC to reduce background signal. A slow acquisition
speed was selected to further reduce the background signal. All
buffers were previously filtered (0.2 mm). MPs quantification was
done using a known concentration of 3 mm latex beads (Sigma), as
described by Combes et al.:53 The number N of a given set of MPs
per milliliter of plasma is calculated with the formula N¼CTBN/
BNC 1000/v. C is the number of events counted in a given dot blot
quadrant, defining each MP type (Figure 1b). TBN is the number of
calibrated dextran beads added in each analyzed sample, BNC is the
number of calibrated beads counted in the FSC/SSC dot plot R1 gate
(Figure 1a). This number was pre-determined (104) and the time of
analysis set accordingly. v is the initial volume (in microliter) of
plasma sample used for one assay.
Statistical analysis
Differences of MP levels before and after ex vivo activation were
analyzed with the Friedman and Mann–Whitney tests. Correlations
between creatinine clearance and MPs levels were evaluated by the
non-parametric Spearman test and by Kruskall–Wallis test, when
subgroups were defined.
Differences of MP levels between nephropathies were evaluated
with the Kruskall–Wallis test with a significance level protected
(0.05) for multiple comparisons. Data were analyzed by BMDP-
system 1.1 software (Meridian marketing group, Sedona, AZ, USA).
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